/

ADMA

ADMA Biologics IncOpen

10.13−0.05 −0.49%USD

NasdaqGM · as of Oct 13, 11:21 ET · 15m delay

Open

10.19

Prev close

10.18

Day range

10.0310.23

52-week range

7.2120.46

Volume

544.28K0.21×

Mkt cap

2.27B

P/E ttm

14.47

Fwd P/E

10.74

EPS ttm

0.7000

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−50.48%

Price Chart

Yahoo Finance · delayed

ADMAOct 13, 2026O 10.19H 10.23L 10.02C 10.13−0.05 (−0.49%)Vol 544.28K

SMA 509.63
SMA 20011.43

1Y change −30.33% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ADMA ADMA Biologics Inc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.49%
1 month: +9.75%
3 months: +14.21%
6 months: −3.43%
Year to date: −44.46%
1 year: −30.38%

Valuation & ownership

Market cap: 2.27B
Enterprise value: 2.35B
P/E (ttm): 14.47
Forward P/E: 10.74
PEG ratio: —
Price / book: 5.59
Price / sales (ttm): 4.43
EV / EBITDA: 10.47
EPS (ttm): 0.7000
EPS (forward): 0.9433
Beta (5y monthly): 0.69
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 223.98M
Float: 219.66M
Short % of float: 11.33%
Short ratio (days): 7.00
Held by insiders: 1.97%
Held by institutions: 92.78%
Avg volume (3m): 2.65M
50-day average: 9.60
200-day average: 11.48
52-week change: −30.38%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 57.2
vs 50-day SMA: +5.18%
vs 200-day SMA: −11.38%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.54%
Realised vol (20d, ann.): 40.8%
From 52-week high: −50.48%
From 52-week low: +40.50%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

17.00

+67.82% implied

Low 12.00Median 17.50High 21.00

Recommendation trend

Now3 / 1 / 0
1m ago4 / 1 / 0

DES

About ADMA Biologics Inc

Yahoo Finance profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 640
Headquarters: Ramsey, NJ, United States
Website: admabiologics.com
Officers: Mr. Adam S. Grossman Co-Founder, President, CEO & Director
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman of the Board

SEAS

Seasonality · ADMA

2013–2026 · monthly returns

Strongest month Jul +9.77%Weakest month Dec −5.78%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.2	-10.0	-42.1	13.8	-22.1	4.9	1.1	11.0	6.8	1.0			−44.5%
2025	-5.8	1.5	21.0	20.0	-16.6	-8.2	2.7	-7.7	-15.1	5.6	23.9	-4.9	+6.4%
2024	14.8	3.3	23.1	-1.2	46.5	17.1	9.8	41.0	15.5	-18.4	23.3	-14.7	+279.4%
2023	-4.9	-3.8	-6.8	1.2	21.5	-9.3	12.5	-7.2	-7.0	-5.6	9.5	22.2	+16.5%
2022	2.8	11.0	13.7	0.5	11.4	-3.4	8.1	26.2	-10.0	16.0	18.4	16.2	+175.2%
2021	13.8	4.1	-23.8	11.4	-10.7	-8.6	-3.1	-13.5	-15.7	14.2	7.0	2.2	−27.7%
2020	-1.0	-26.4	-1.2	2.4	11.5	-10.9	21.8	-28.6	-6.3	-16.7	2.5	-4.4	−51.2%
2019	23.4	38.6	-7.3	22.2	-10.4	-6.7	-6.5	23.8	-0.7	9.9	-2.9	-15.8	+67.4%
2018	15.9	0.8	22.7	8.0	9.1	-16.8	44.6	-2.0	-2.8	-13.5	-1.9	-54.6	−25.5%
2017	-0.2	-8.6	4.5	-7.6	-18.0	0.0	-6.8	0.0	-10.7	-24.0	23.9	10.7	−37.3%
2016	-25.2	-21.3	70.3	-15.5	13.3	-23.2	31.9	-27.3	26.8	-22.9	-0.7	-7.6	−36.6%
2015	-3.3	-11.7	2.7	-14.2	1.8	8.2	0.6	-1.0	-9.4	9.8	0.0	-12.1	−27.8%
2014	10.3	-1.0	-1.9	-7.2	12.9	11.4	1.5	-5.6	10.2	14.1	5.3	-9.7	+43.2%
2013											-3.6	-2.5	−6.0%

INSD

Insider Activity · ADMA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 15, 2026	Kohler TerryChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	85.1K	—
May 26, 2026	Grossman Jerrold BDirector	Purchase at price 7.91 per share.	6.4K	$50.62K
May 11, 2026	Grossman Jerrold BDirector	Purchase at price 8.01 per share.	12.5K	$100.13K
May 10, 2026	Grossman Jerrold BDirector	Purchase at price 8.01 per share.	12.5K	$100.13K
Mar 16, 2026	Guiheen Lawrence PDirector	Stock Gift at price 0.00 per share.	30K	—
Mar 15, 2026	Grossman Adam SChief Executive Officer	Sale at price 15.16 per share.	21K	$318.36K
Mar 15, 2026	Grossman Adam SChief Executive Officer	Conversion of Exercise of derivative security at price 5.40 per share.	15K	$81.00K
Mar 12, 2026	Guiheen Lawrence PDirector	Conversion of Exercise of derivative security at price 3.66 per share.	30K	$109.80K
Mar 8, 2026	Kestenberg-Messina Kaitlin M.Officer	Sale at price 15.63 per share.	10.1K	$157.80K
Mar 8, 2026	Kestenberg-Messina Kaitlin M.Officer	Conversion of Exercise of derivative security at price 1.55 - 5.00 per share.	10.1K	$32.33K
Mar 5, 2026	Elms Steven ADirector	Purchase at price 15.39 - 15.67 per share.	14K	$217.42K
Feb 16, 2026	Grossman Adam SChief Executive Officer	Sale at price 16.08 per share.	21K	$337.68K
Feb 16, 2026	Grossman Adam SChief Executive Officer	Conversion of Exercise of derivative security at price 5.40 per share.	15K	$81.00K
Feb 8, 2026	Guiheen Lawrence PDirector	Stock Award(Grant) at price 0.00 per share.	10.7K	—
Feb 8, 2026	Finger Alison CecilyDirector	Stock Award(Grant) at price 0.00 per share.	10.7K	—
Feb 8, 2026	Kwon Young T. Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	10.7K	—
Feb 8, 2026	Elms Steven ADirector	Stock Award(Grant) at price 0.00 per share.	10.7K	—
Feb 8, 2026	Salas Eduardo ReneDirector	Stock Award(Grant) at price 0.00 per share.	10.7K	—
Feb 8, 2026	Kestenberg-Messina Kaitlin M.Officer	Stock Award(Grant) at price 0.00 per share.	91.6K	—
Feb 8, 2026	Grossman Jerrold BDirector	Stock Award(Grant) at price 0.00 per share.	10.7K	—

13F

Investors Holding ADMA

latest 13F filings of 29 followed managers

Investors holding ADMA
Investor	Value	Of portfolio	Shares	Change	Quarter
Duquesne Family Office · Stanley Druckenmiller	$23.3M	0.45%	2.78M	+80%	Q2 2026
Fundsmith · Terry Smith	$13.8M	0.10%	1.65M	—	Q2 2026
Renaissance Technologies	$5.5M	0.01%	652.53K	−48%	Q2 2026
Bridgewater Associates · Ray Dalio	$3.4M	0.01%	401.06K	−15%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ADMA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ADMA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ADMA Biologics Inc

Seasonality · ADMA

Insider Activity · ADMA

Congress Trades · ADMA

Investors Holding ADMA

Investors Holding ADMA

Congress Trades · ADMA

Insider Activity · ADMA

Seasonality · ADMA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ADMA Biologics Inc

Financial Snapshot

Earnings & Dividends

News